NCT04000737: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 125 | US, RoW | YIV-906+Sorafenib, Placebo+Sorafenib | Yiviva Inc. | Advanced Hepatocellular Carcinoma | 12/23 | 05/24 | | |
TCOG T5221, NCT05026905: A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 66 | RoW | Gemcitabine 1000 mg, Gemcitabine, Nab paclitaxel, nab-paclitaxel, S1, S-1, leucovorin, Calcium Folinate tablet, Oxaliplatin | National Health Research Institutes, Taiwan, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Phase II, Open-label, Parallel 2-arm, Multi-center | 12/24 | 12/27 | | |
